Literature DB >> 34483761

Contrasting Typical and Atypical Antipsychotic Drugs.

Herbert Y Meltzer, Erick Gadaleta.   

Abstract

The beliefs that antipsychotic drugs (APDs) are 1) effective only to treat delusions and hallucinations (positive symptoms), 2) that typical and atypical APDs differ only in ability to cause extrapyramidal side effects, and 3) that their efficacy as antipsychotics is due solely to their dopamine D2 receptor blockade are outmoded concepts that prevent clinicians from achieving optimal clinical results when prescribing an APD. Atypical APDs are often more effective than typical APDs in treating negative symptoms, cognitive impairment, and mood symptoms as well as reducing the risk for suicide and decreasing aggression. This applies not only to those diagnosed with schizophrenia or schizoaffective disorder but also to bipolar disorder, major depression, and other psychiatric diagnoses. The greater advantage of an atypical APD is not evident in all patients for every atypical APD due, in part, to individual differences in genetic and epigenetic endowment and differences in the pharmacology of the atypical APDs, their mode of action being far more complex than that of the typical APDs. A common misconception is that among the atypical APDs, only clozapine is effective for reducing psychosis in treatment-resistant schizophrenia. Aripiprazole, lurasidone, olanzapine, and risperidone also can be more effective than typical APDs for treatment-resistant schizophrenia; clozapine is uniquely indicated for reducing the risk for suicide. The ability of the atypical APDs to improve cognition and negative symptoms in some patients together with lower propensity to cause tardive dyskinesia (an underappreciated advantage) leads to better overall outcomes. These advantages of the atypical APDs in efficacy and safety are due, in part, to initiation of synaptic plasticity via direct and indirect effects of the atypical APDs on a variety of proteins, especially G proteins, and release of neurotrophins (e.g., brain-derived neurotrophic factor). The typical APDs beneficial effects on psychosis are mainly the result of D2 receptor blockade, which can be associated with serious side effects and lack of tolerability.
Copyright © 2021 by the American Psychiatric Association.

Entities:  

Keywords:  Antipsychotics

Year:  2021        PMID: 34483761      PMCID: PMC8412155          DOI: 10.1176/appi.focus.20200051

Source DB:  PubMed          Journal:  Focus (Am Psychiatr Publ)        ISSN: 1541-4094


  117 in total

1.  DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1.

Authors:  H C Hemmings; P Greengard; H Y Tung; P Cohen
Journal:  Nature       Date:  1984 Aug 9-15       Impact factor: 49.962

2.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

Review 3.  A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

Authors:  Neil D Woodward; Scot E Purdon; Herbert Y Meltzer; David H Zald
Journal:  Int J Neuropsychopharmacol       Date:  2005-03-23       Impact factor: 5.176

Review 4.  The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.

Authors:  H Y Meltzer; S R McGurk
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

5.  Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.

Authors:  J P McEvoy; G E Hogarty; S Steingard
Journal:  Arch Gen Psychiatry       Date:  1991-08

6.  The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone.

Authors:  Tomoko Horisawa; Hiroyuki Nishikawa; Satoko Toma; Atsushi Ikeda; Masakuni Horiguchi; Michiko Ono; Takeo Ishiyama; Mutsuo Taiji
Journal:  Behav Brain Res       Date:  2013-01-31       Impact factor: 3.332

7.  A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment.

Authors:  Philip D Harvey; Emilio Sacchetti; Alessandro Galluzzo; Fabio Romeo; Barbara Gorini; Robert M Bilder; Antony D Loebel
Journal:  Schizophr Res       Date:  2008-02-20       Impact factor: 4.939

8.  Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism.

Authors:  Junji Ichikawa; Zhu Li; Jin Dai; Herbert Y Meltzer
Journal:  Brain Res       Date:  2002-11-29       Impact factor: 3.252

9.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Authors:  Richard S E Keefe; Robert M Bilder; Sonia M Davis; Philip D Harvey; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; George Capuano; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Clarence E Davis; John K Hsiao; Jeffrey A Lieberman
Journal:  Arch Gen Psychiatry       Date:  2007-06

10.  Fifty years chlorpromazine: a historical perspective.

Authors:  Thomas A Ban
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

View more
  2 in total

1.  Case Report: Severe Side Effects Following Treatment With First Generation Antipsychotics While Cariprazine Leads to Full Recovery.

Authors:  Maris Taube
Journal:  Front Psychiatry       Date:  2021-12-14       Impact factor: 4.157

2.  Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial.

Authors:  Bhanu Gupta; Kok-Seng Chee; Li-Qi Neo; Charmaine Tang; Jayaraman Hariram; Geoffrey Chern-Yee Tan; Swapna Verma; Sutapa Basu; Deva-Priya Appan; Chan-Chun Ting; Edimansyah Abdin; Jimmy Lee
Journal:  Ther Adv Psychopharmacol       Date:  2021-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.